<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051922</url>
  </required_header>
  <id_info>
    <org_study_id>P01AI045142</org_study_id>
    <secondary_id>P01AI045142</secondary_id>
    <nct_id>NCT00051922</nct_id>
  </id_info>
  <brief_title>Development of a New HIV Vaccine</brief_title>
  <official_title>Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the
      immune response to the vaccine. Only some HIV genes are used to make the vaccine and
      therefore the vaccine cannot itself cause HIV or AIDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 presents several challenges to vaccine design, including: 1) high mutation rates
      resulting in tremendous diversity of virus envelope, the target of neutralizing antibody,
      such that antibody elicited to one envelope may not protect from virus with a distinct
      envelope; 2) envelope from infected persons differs from envelopes obtained from T-cell line
      cultures, the usual source of envelope for vaccines; and 3) envelope glycoprotein exists as
      oligomers on the virion surface, not as the monomers used in previous vaccines. This study
      will test a new vaccine that has been designed to meet these challenges by delivering
      diverse, patient-derived, oligomeric envelopes to induce multiple type-specific responses
      capable of recognizing native envelope on natural variants. The vaccine vector used in this
      vaccine trial is recombinant vaccinia virus based on the NYCDH vaccinia isolate.

      Participants in this study will receive the PolyEnv1 HIV vaccine and will be followed for one
      year. Laboratory tests will be performed at 10 study visits to monitor the participants'
      immunologic response and assess the safety of the vaccine. Patients will also have numerous
      HIV tests throughout the study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability and safety of the PolyEnv1 vaccine</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive vaccine and will be followed for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PolyEnv1</intervention_name>
    <description>Recombinant vaccinia virus vaccine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 negative

          -  Availability for one year of follow-up

          -  No evidence of previous smallpox vaccination

          -  Acceptable methods of contraception

        Exclusion Criteria:

          -  Immunosuppressive or chronic illness

          -  Medical or psychological conditions which could affect compliance

          -  High risk for HIV infection

          -  Live attenuated vaccines within 60 days

          -  Experimental agents within 30 days

          -  Blood products within past 6 months

          -  Eczema

          -  Pregnant or lactating women

          -  Household contact with immunodeficient person, pregnant woman, or child less than 12
             months of age

          -  Allergy to gentamicin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>32 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Flynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Member</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia L. Hurwitz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Member</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>Click here for more information about St. Jude Children's Research Hospital.</description>
  </link>
  <reference>
    <citation>Brown SA, Stambas J, Zhan X, Slobod KS, Coleclough C, Zirkel A, Surman S, White SW, Doherty PC, Hurwitz JL. Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. J Immunol. 2003 Oct 15;171(8):4140-8.</citation>
    <PMID>14530336</PMID>
  </reference>
  <reference>
    <citation>Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. Vaccine. 1999 Mar 17;17(11-12):1567-72.</citation>
    <PMID>10195794</PMID>
  </reference>
  <reference>
    <citation>Lockey TD, Slobod KS, Caver TE, D'Costa S, Owens RJ, McClure HM, Compans RW, Hurwitz JL. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. Immunol Res. 2000;21(1):7-21.</citation>
    <PMID>10803879</PMID>
  </reference>
  <reference>
    <citation>Rencher SD, Lockey TD, Srinivas RV, Owens RJ, Hurwitz JL. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants. Vaccine. 1997 Feb;15(3):265-72. Erratum in: Vaccine 2000 Mar 17;18(18):1969. Vaccine. 2010 Apr 26;28(19):3507.</citation>
    <PMID>9139484</PMID>
  </reference>
  <reference>
    <citation>Rencher SD, Slobod KS, Dawson DH, Lockey TD, Hurwitz JL. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses. 1995 Sep;11(9):1131-3.</citation>
    <PMID>8554911</PMID>
  </reference>
  <reference>
    <citation>Richmond JF, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Feny√∂ EM, Hurwitz JL, Montefiori DC, Robinson HL. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology. 1997 Apr 14;230(2):265-74.</citation>
    <PMID>9143282</PMID>
  </reference>
  <reference>
    <citation>Slobod KS, Bonsignori M, Brown SA, Zhan X, Stambas J, Hurwitz JL. HIV vaccines: brief review and discussion of future directions. Expert Rev Vaccines. 2005 Jun;4(3):305-13. Review.</citation>
    <PMID>16026246</PMID>
  </reference>
  <reference>
    <citation>Slobod KS, Coleclough C, Brown SA, Stambas J, Zhan X, Surman S, Jones BG, Zirkel A, Freiden PJ, Brown B, Sealy R, Bonsignori M, Hurwitz JL. Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary? AIDS Res Ther. 2005 Apr 28;2(1):3.</citation>
    <PMID>15860130</PMID>
  </reference>
  <reference>
    <citation>Surman S, Lockey TD, Slobod KS, Jones B, Riberdy JM, White SW, Doherty PC, Hurwitz JL. Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4587-92. Epub 2001 Apr 3.</citation>
    <PMID>11287644</PMID>
  </reference>
  <reference>
    <citation>Zhan X, Slobod KS, Surman S, Brown SA, Lockey TD, Coleclough C, Doherty PC, Hurwitz JL. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol. 2003 Apr;77(7):4231-6.</citation>
    <PMID>12634380</PMID>
  </reference>
  <results_reference>
    <citation>Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ, Doherty PC, Hurwitz JL. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis. 2004 Feb;23(2):106-10. Epub 2004 Jan 20.</citation>
    <PMID>14735404</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2003</study_first_submitted>
  <study_first_submitted_qc>January 21, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2003</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Patricia Flynn, MD</name_title>
    <organization>St. Jude's Children's Hospital</organization>
  </responsible_party>
  <keyword>HIV Preventive Vaccine</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

